

# Takayuki Yoshino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2628780/publications.pdf>

Version: 2024-02-01

157  
papers

16,894  
citations

66343

42  
h-index

16183

124  
g-index

161  
all docs

161  
docs citations

161  
times ranked

14044  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 37-45.	2.4	9
2	DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. <i>Cancer Science</i> , 2022, 113, 1531-1534.	3.9	6
3	The Essentials of Multiomics. <i>Oncologist</i> , 2022, 27, 272-284.	3.7	11
4	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	7.0	62
5	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	3
6	Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 126-136.	1.4	1
7	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	3.0	8
8	Impact of Circulating Tumor DNAâ€“Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	3.0	33
9	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2022, 8, 760.	7.1	35
10	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	1.6	9
11	Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Antiâ€“PD-1 Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 2110-2117.	7.0	30
12	Rapid Screening Using Pathomorphologic Interpretation to Detect <i>BRAF</i> V600E Mutation and Microsatellite Instability in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2623-2632.	7.0	4
13	ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. <i>Lancet Oncology</i> , The, 2022, 23, 463-464.	10.7	3
14	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100535.	3.0	29
15	Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. <i>Future Oncology</i> , 2022, 18, 2351-2360.	2.4	22
16	Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database. <i>Current Oncology</i> , 2022, 29, 3433-3448.	2.2	2
17	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. <i>Targeted Oncology</i> , 2022, , 1.	3.6	1
18	Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3419-3429.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1413-1420.	2.2	2
20	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 3480-3488.	7.0	8
21	Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 113-120.e1.	2.3	22
22	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	2.2	49
23	FMSâ€like tyrosine kinase 3 ( FLT3 ) amplification in patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 314-322.	3.9	8
24	Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 700-706.	1.3	8
25	The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 443-449.	2.2	24
26	Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen.. <i>Journal of Clinical Oncology</i> , 2021, 39, 106-106.	1.6	3
27	Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 631-641.	1.6	63
28	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	7.0	39
29	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600Eâ€Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-284.	1.6	254
30	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	1.6	84
31	Landscape of genomic alterations of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Project.. <i>Journal of Clinical Oncology</i> , 2021, 39, 152-152.	1.6	3
32	A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3714-3724.	7.0	61
33	Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1238-1247.	2.2	2
34	Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with <i>HER2</i> (<i>ERBB2</i>) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3555-3555.	1.6	11
35	Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 2541-2541.	1.6	10
36	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789.	10.7	234

#	ARTICLE	IF	CITATIONS
37	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 674.	2.6	19
38	CIRCULATEâ€‘Japan: Circulating tumor DNAâ€‘guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 2915-2920.	3.9	74
39	Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1459-1463.	0.8	4
40	The Prognostic Impact of <i>KRAS</i> G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. <i>Oncologist</i> , 2021, 26, 845-853.	3.7	26
41	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. <i>Cancer Treatment Reviews</i> , 2021, 98, 102218.	7.7	33
42	Phase I study of napabucasin in combination with FOLFIRI+bevacizumab in Japanese patients with metastatic colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2017-2024.	2.2	8
43	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	7.0	27
44	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3151-3162.	2.4	14
45	SCRUMâ€‘Japan GIâ€‘SCREEN and MONSTARâ€‘SCREEN: Path to the realization of biomarkerâ€‘guided precision oncology in advanced solid tumors. <i>Cancer Science</i> , 2021, 112, 4425-4432.	3.9	24
46	<i>BRAF</i> V600E potentially determines â€‘Oncological Resectabilityâ€‘for â€‘Technically Resectableâ€‘colorectal liver metastases. <i>Cancer Medicine</i> , 2021, 10, 6998-7011.	2.8	7
47	ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve â€‘Precision Onco-Surgeryâ€‘in Resectable Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 4756-4757.	1.5	0
48	Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 4744-4755.	1.5	23
49	Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110091.	3.2	4
50	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4019.	1.6	45
51	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1899-1903.	30.7	110
52	Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. <i>Future Oncology</i> , 2021, 17, 5013-5022.	2.4	2
53	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1-42.	2.2	1,123
54	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instabilityâ€‘High/Mismatch Repairâ€‘Deficient Metastatic Colorectal Cancer: KEYNOTE-164. <i>Journal of Clinical Oncology</i> , 2020, 38, 11-19.	1.6	623

#	ARTICLE	IF	CITATIONS
55	International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i> -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. <i>JCO Precision Oncology</i> , 2020, 4, 6-19.	3.0	29
56	Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN. <i>Pathology International</i> , 2020, 70, 932-942.	1.3	19
57	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	30.7	209
58	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	7.0	44
59	Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BITS Study). <i>Oncologist</i> , 2020, 25, e1855-e1863.	3.7	28
60	Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan. <i>Annals of Surgical Oncology</i> , 2020, 27, 3307-3315.	1.5	20
61	Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab. <i>JCO Precision Oncology</i> , 2020, 4, 1407-1413.	3.0	9
62	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA). <i>Lancet Oncology</i> , 2020, 21, 1620-1629.	10.7	152
63	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2207-2218.	27.0	1,513
64	Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094237.	3.2	7
65	Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. <i>ESMO Open</i> , 2020, 5, e000775.	4.5	22
66	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 893-903.	5.3	20
67	Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 855-862.	2.3	24
68	ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into "Precision Oncosurgery" in Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3316-3317.	1.5	3
69	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020, 86, 101993.	7.7	61
70	BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000624.	4.5	15
71	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database. <i>Journal of Clinical Oncology</i> , 2020, 38, 4099-4099.	1.6	1
72	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 69-76.	5.3	45

#	ARTICLE	IF	CITATIONS
73	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	7.0	152
74	Activity on Nationwide Cancer Genome Screening Project for Metastatic Colorectal Cancer in Japan; SCRUM-Japan GI-SCREEN. <i>Annals of Oncology</i> , 2019, 30, vi46.	1.2	1
75	Exploration of potential prognostic biomarkers in aflibercept plus <scp>FOLFIRI</scp> in Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 3565-3572.	3.9	11
76	Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1574.	7.1	74
77	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. <i>Clinical Colorectal Cancer</i> , 2019, 18, 269-279.e5.	2.3	4
78	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600Eâ€“Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	27.0	918
79	JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1269-1277.	2.3	15
80	A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 982-986.	6.4	64
81	Phase <scp>II</scp> trial of aflibercept with <scp>FOLFIRI</scp> as a secondâ€“line treatment for Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 1032-1043.	3.9	30
82	Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000590.	4.5	1
83	Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. <i>Oncologist</i> , 2019, 24, e450-e457.	3.7	28
84	Response to Anti-EGFR Therapy in Patients with BRAF non-V600â€“Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7089-7097.	7.0	79
85	HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naâ€“ve, HER2-amplified metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000530.	4.5	7
86	Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1253.	2.6	26
87	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	2.3	53
88	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	5.3	124
89	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	9.4	448
90	Response to Letter to the Editor, â€“Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,â€™ by Ibrahim etÂ€“. <i>European Journal of Cancer</i> , 2018, 92, 121-122.	2.8	0



#	ARTICLE	IF	CITATIONS
91	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 263-270.	8.1	121
92	Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. <i>Oncogene</i> , 2018, 37, 1775-1787.	5.9	28
93	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 1310-1318.	3.7	40
94	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188.	27.0	699
95	Reply to "Comment on "Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BRFAC) study". <i>British Journal of Cancer</i> . 2018. 118. 1278-1279.	6.4	0
96	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1-34.	2.2	1,187
97	Integrated safety summary for trifluridine/tipiracil (TAS-102). <i>Anti-Cancer Drugs</i> , 2018, 29, 89-96.	1.4	12
98	Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study. <i>Neoplasia</i> , 2018, 20, 1219-1226.	5.3	21
99	Utility of the quasi-homomorphic variation range in unresectable metastatic colorectal cancer patients. <i>Cancer Science</i> , 2018, 109, 3411-3415.	3.9	35
100	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq0 0,0rgBT /Overlock 10	3.9	38
101	Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. <i>ESMO Open</i> . 2018, 3, e000411.	4.5	13
102	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 198-205.	2.3	57
103	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. <i>Clinical Colorectal Cancer</i> , 2018, 17, e719-e732.	2.3	10
104	Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. <i>ESMO Open</i> , 2018, 3, e000354.	4.5	23
105	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3530-3530.	1.6	10
106	International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3594-3594.	1.6	5
107	The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4050-4050.	1.6	13
108	Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 36.	2.6	5

#	ARTICLE	IF	CITATIONS
109	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS ( KRAS/NRAS ) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	2.3	13
110	Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e39-e44.	2.3	12
111	Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. <i>European Journal of Cancer</i> , 2017, 78, 61-69.	2.8	25
112	Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 107-116.	2.3	4
113	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1172-1181.	10.7	111
114	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECURSE trial. <i>ESMO Open</i> , 2017, 2, e000261.	4.5	22
115	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. <i>British Journal of Cancer</i> , 2017, 117, 1450-1458.	6.4	52
116	CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3619-TPS3619.	1.6	12
117	Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. <i>Clinical Colorectal Cancer</i> , 2016, 15, e109-e115.	2.3	20
118	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. <i>BMC Cancer</i> , 2016, 16, 467.	2.6	57
119	Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. <i>Cancer Science</i> , 2016, 107, 659-665.	3.9	16
120	Adjuvant Chemotherapy for Colon Cancer: Guidelines and Clinical Trials in Japan. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 289-295.	0.5	1
121	12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2906-2913.	1.6	62
122	TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study. <i>Clinical Colorectal Cancer</i> , 2016, 15, e205-e211.	2.3	24
123	An international phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: Compliance and safety of the phase III Japanese ACHIEVE trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3550-3550.	1.6	2
124	The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3591-3591.	1.6	4
125	Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. <i>BMC Cancer</i> , 2015, 15, 718.	2.6	11
126	5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. <i>Cancer Management and Research</i> , 2015, 7, 165.	1.9	10



#	ARTICLE	IF	CITATIONS
127	Japanese Society of Medical Oncology Clinical Guidelines: <i>RAS</i> ( <i>KRAS</i> / <i>NRAS</i> ) mutation testing in colorectal cancer patients. <i>Cancer Science</i> , 2015, 106, 324-327.	3.9	37
128	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. <i>Investigational New Drugs</i> , 2015, 33, 740-750.	2.6	94
129	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , 2015, 16, 937-948.	10.7	286
130	A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 547-553.	2.3	4
131	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology</i> , 2015, 16, 499-508.	10.7	753
132	A retrospective observational study of clinicopathological features of <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> and <i>PIK3CA</i> mutations in Japanese patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 258.	2.6	93
133	Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 75-84.	2.3	26
134	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1909-1919.	27.0	1,027
135	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 207-239.	2.2	548
136	Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS Key Testing) Prospective, Multicenter Study. <i>EBioMedicine</i> , 2015, 2, 317-323.	6.1	54
137	Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 1068-1077.	2.6	28
138	Phase 3 RECURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3564-3564.	1.6	7
139	Clinical impact of expanded <i>BRAF</i> mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR) Tj ETQq1 1 0.784314 rgBT /Overl 573-573.	1.6	2
140	Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. <i>Anticancer Research</i> , 2015, 35, 4003-7.	1.1	20
141	Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect. <i>PLoS ONE</i> , 2014, 9, e105160.	2.5	5
142	Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3655-TPS3655.	1.6	1
143	Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. <i>Journal of Bioscience and Bioengineering</i> , 2013, 116, 768-773.	2.2	8
144	A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 910-917.	2.6	26

#	ARTICLE	IF	CITATIONS
145	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2013, 381, 303-312.	13.7	2,276
146	Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. <i>BMC Cancer</i> , 2013, 13, 405.	2.6	42
147	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 261-269.	0.5	94
148	Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 524-531.	1.3	67
149	KRAS Mutational Status in Japanese Patients with Colorectal Cancer: Results from a Nationwide, Multicenter, Cross-sectional Study. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 706-712.	1.3	39
150	Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harboring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 1146-1151.	1.3	16
151	TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 993-1001.	10.7	267
152	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2012, 17, 1-29.	2.2	658
153	Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naïve colorectal cancer. <i>Anticancer Research</i> , 2012, 32, 973-9.	1.1	5
154	Feasibility and Robustness of Amplification Refractory Mutation System (ARMS)-based KRAS Testing Using Clinically Available Formalin-fixed, Paraffin-embedded Samples of Colorectal Cancers. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 52-56.	1.3	13
155	A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 557-564.	2.3	11
156	Efficacy and Safety of an Irinotecan plus Bolus 5-Fluorouracil and L-Leucovorin Regimen for Metastatic Colorectal Cancer in Japanese Patients: Experience in a Single Institution in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 686-691.	1.3	10
157	NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	1